Expertise in
12
conditions

Jan-inge I. Henter

Stockholm, AB, SE 
Expertise in
12
conditions
Stockholm, AB, SE 

Overview

Jan-inge Henter practices practicing medicine in Stockholm, Sweden.

Henter is highly rated in 12 conditions, according to our data. Their clinical expertise encompasses Hemophagocytic Lymphohistiocytosis, Reticulohistiocytoma, Histiocytosis, Non-Langerhans-Cell Histiocytosis, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 123 peer reviewed articles and participating in 2 clinical trials.

Locations

Stockholm, AB, Sweden
Other Locations
Solna, AB, Sweden
Huddinge, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

123 Total Publications

Machine learning for prediction in secondary hemophagocytic lymphohistiocytosis: real progress, real limits, and the potential of synthetic data.
Machine learning for prediction in secondary hemophagocytic lymphohistiocytosis: real progress, real limits, and the potential of synthetic data.
Journal: Intensive care medicine
Published: June 29, 2026

Frequently Asked Questions about Jan-inge I. Henter

Is Jan-inge I. Henter a top-rated expert for Hemophagocytic Lymphohistiocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Jan-inge I. Henter is classified as an Elite expert for Hemophagocytic Lymphohistiocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jan-inge I. Henter participate in research or clinical trials?

Yes. Jan-inge I. Henter has published 123 articles and abstracts on conditions like Hemophagocytic Lymphohistiocytosis. You can view a list of Jan-inge I. Henter's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Henter's expertise for a condition
ConditionClose
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile